INDIANAPOLIS, Indiana — Diagnostic ID, which offers a system designed to stop mismatching biopsy samples with the wrong patients, is raising $3 million through debt, according to a filing with the Securities & Exchange Commission.
The 1-year-old company offers a service called Know Error that uses a three-step process to cut down on so-called switching errors of prostate biopsies due to mislabeling or misplaced slides, among other things. A swab from a patient’s cheek is sent to a lab, analyzed and assigned a unique barcode identification. Pathology results are then compared to the original swab to confirm a DNA match.
Automation has already drastically cut down on mislabeling errors, though errors can still occur particularly when samples are moved from one place to another — and mistakes usually have nothing to do with the tests themselves. Many errors occur before or after the test is complete.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
[Photo courtesy of Flickr user sflovestory]
